CARTEOLOL HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CARTEOLOL HYDROCHLORIDE (CARTEOLOL HYDROCHLORIDE).
Non-selective beta-adrenergic receptor antagonist (beta-blocker) with intrinsic sympathomimetic activity (ISA) and weak local anesthetic (membrane-stabilizing) activity. Reduces intraocular pressure by decreasing aqueous humor production.
| Metabolism | Primarily hepatic metabolism via glucuronidation; minimal CYP450 involvement. Systemic absorption after ophthalmic administration is limited. |
| Excretion | Renal excretion of unchanged drug and active metabolite (8-hydroxycarteolol) accounts for 50-70% of elimination. Biliary/fecal excretion is minimal (<10%). |
| Half-life | Terminal elimination half-life is 5-6 hours in patients with normal renal function; may extend to 24-36 hours in severe renal impairment. |
| Protein binding | Approximately 23% bound to plasma proteins (mainly albumin). |
| Volume of Distribution | Volume of distribution is approximately 4 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Ophthalmic: Systemic bioavailability is approximately 10-20% due to nasolacrimal drainage and first-pass metabolism. |
| Onset of Action | Ophthalmic: Onset of ocular hypotensive effect within 1 hour. Oral: Not applicable (not used systemically). |
| Duration of Action | Ophthalmic: Duration of intraocular pressure reduction is approximately 12-24 hours, supporting once or twice daily dosing. |
Ophthalmic: Instill 1 drop of 1% or 2% solution into affected eye(s) twice daily. Oral: 2.5 mg to 5 mg once daily; may increase to 10 mg once daily if needed. Maximum dose 10 mg daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | For oral administration: GFR 30-60 mL/min: 2.5 mg once daily. GFR <30 mL/min: 2.5 mg every 48 hours or 50% reduction in frequency. Hemodialysis: 2.5 mg after dialysis on dialysis days. |
| Liver impairment | Child-Pugh Class A: No adjustment. Class B: Reduce dose by 50%. Class C: Use with extreme caution; no specific dosing guidelines; consider 50% reduction or alternative therapy. |
| Pediatric use | Safety and efficacy not established for oral use. Ophthalmic: Limited data; use same as adult for hypertension or glaucoma, but monitor closely. Weight-based dosing not defined. |
| Geriatric use | Start with lowest available dose (2.5 mg orally once daily). Ophthalmic: Use 1% solution. Monitor heart rate and blood pressure due to increased risk of bradycardia and hypotension. Adjust based on renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CARTEOLOL HYDROCHLORIDE (CARTEOLOL HYDROCHLORIDE).
| Breastfeeding | Carteolol is excreted into breast milk. The M/P ratio is unknown. Due to potential for infant bradycardia and hypoglycemia, caution is advised. Use only if clearly needed, and monitor infant for signs of beta-blockade. |
| Teratogenic Risk | Carteolol hydrochloride, a non-selective beta-blocker, crosses the placenta. First trimester: Limited human data, but animal studies show no teratogenic effects. However, beta-blockers are associated with fetal growth restriction. Second and third trimesters: Risk of fetal bradycardia, hypoglycemia, and respiratory depression. Use only if benefit outweighs risk. |
■ FDA Black Box Warning
No FDA black box warning exists for ophthalmic carteolol.
| Serious Effects |
["Bronchial asthma or history of bronchial asthma","Chronic obstructive pulmonary disease (COPD)","Sinus bradycardia","Second- or third-degree atrioventricular block","Cardiogenic shock","Overt cardiac failure"]
| Precautions | ["Systemic absorption may cause bronchospasm in patients with asthma or COPD","May mask signs of hypoglycemia in diabetic patients","May mask signs of hyperthyroidism","May exacerbate cardiac failure or cause bradycardia","Use caution in patients with sinus node dysfunction or AV block","May cause ocular irritation or dry eye"] |
| Food/Dietary | No specific food interactions reported. Avoid excessive alcohol intake, which may enhance hypotensive effects. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and signs of heart failure. Fetal monitoring includes heart rate, growth via ultrasound, and assessment for bradycardia. Neonates should be observed for bradycardia, hypoglycemia, and respiratory depression for 48 hours postpartum. |
| Fertility Effects | No specific studies on human fertility. Beta-blockers may impair male and female reproductive function through effects on autonomic nervous system; however, clinical significance is unknown. |
| Clinical Pearls | Carteolol is a non-selective beta-blocker with intrinsic sympathomimetic activity (ISA), which may reduce bradycardia and bronchospasm risk. It is primarily used for glaucoma, but systemic absorption can cause beta-blockade effects. Monitor heart rate and blood pressure in patients with cardiovascular disease. Avoid in patients with sinus bradycardia, heart block, or uncontrolled heart failure. Use with caution in COPD/asthma due to potential bronchospasm. When used for glaucoma, it may mask symptoms of hypoglycemia in diabetic patients. |
| Patient Advice | Apply the prescribed number of drops into the affected eye(s) as directed, usually once or twice daily. · Do not touch the dropper tip to your eye or any surface to avoid contamination. · Close your eyes for 1-2 minutes after instillation and apply gentle pressure to the inner corner of the eye (nasolacrimal occlusion) to reduce systemic absorption. · Wash hands before and after use. Wait at least 5 minutes between different eye medications. · Avoid driving or operating machinery if you experience blurred vision after application. · Notify your doctor if you experience dizziness, fainting, slow heartbeat, difficulty breathing, or eye pain. · Do not discontinue abruptly if used for systemic effects; taper under medical supervision. · Inform your doctor if you have asthma, COPD, diabetes, thyroid disease, or heart problems. |